ADMA Biologics (ADMA) Received its Third Buy in a Row


After Maxim Group and H.C. Wainwright gave ADMA Biologics (NASDAQ: ADMA) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Leland Gershell reiterated a Buy rating on ADMA Biologics yesterday and set a price target of $13. The company’s shares closed yesterday at $5.16.

Gershell said:

“3Q18 net loss per share was $0.33 vs. our $0.32E. ADMA continues to execute according to plan as it works toward expanding its footprint in the plasma-derived therapeutics space. With 1H19 set up to see Bivigam return to the market (~$60M/yr prior sales) and RI-002 to receive FDA approval (est. $200M+ market oppy) following extensive and successful manufacturing remediation per recent status upgrade, we believe the market is over-discounting ADMA’s (near-term) regulatory and (longer- term) commercial prospects. We reiterate our Outperform rating and $13 PT.”

According to TipRanks.com, Gershell is a 1-star analyst with an average return of -7.8% and a 20.0% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Avenue Therapeutics Inc, Evofem Biosciences Inc, and AzurRx BioPharma Inc.

Currently, the analyst consensus on ADMA Biologics is a Strong Buy with an average price target of $13, implying a 151.9% upside from current levels. In a report issued on October 30, H.C. Wainwright also initiated coverage with a Buy rating on the stock with a $17 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $6.96 and a one-year low of $2.42. Currently, ADMA Biologics has an average volume of 211.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

ADMA Biologics, Inc. is a biopharmaceutical company. It develops, manufactures, and intends to commercialize in human plasma and plasma-derived therapeutics. It operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts